Literature DB >> 11522630

scid Thymocytes with TCRbeta gene rearrangements are targets for the oncogenic effect of SCL and LMO1 transgenes.

D S Chervinsky1, D H Lam, M P Melman, K W Gross, P D Aplan.   

Abstract

SCL and LMO1 were both discovered by virtue of their activation by chromosomaltranslocation in patients with T-cell acute lymphoblastic leukemia (T-ALL). Overexpression of SCL and LMO1 in the thymus of transgenic mice leads to T-ALL at a young age. scid (severe combined immunodeficient) mice are unable to efficiently recombine antigen receptor genes and consequently display a developmental block at the CD4-CD8- to CD4+CD8+ transition. To test the hypothesis that this developmental block would protect SCL/LMO1 transgenic mice from developing T-ALL, we crossed the SCL and LMO1 transgenes onto a scid background. The age of onset for T-ALL in the SCL/LMO1/scid mice was significantly delayed (P < 0.001) compared with SCL/LMO1/wild-type mice. Intriguingly, all of the SCL/LMO1/scid malignancies displayed clonal, in-frame TCRbeta gene rearrangements. Taken together, these findings suggest that the "leaky" scid thymocyte that undergoes a productive TCRbeta gene rearrangement is susceptible to the oncogenic action of SCL and LMO1 and additionally suggests that TCRbeta gene rearrangements may be required for the oncogenic action of SCL and LMO1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522630

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma.

Authors:  Ying-Wei Lin; Rebecca A Nichols; John J Letterio; Peter D Aplan
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

2.  Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes.

Authors:  Mathieu Tremblay; Cédric S Tremblay; Sabine Herblot; Peter D Aplan; Josée Hébert; Claude Perreault; Trang Hoang
Journal:  Genes Dev       Date:  2010-06-01       Impact factor: 11.361

3.  Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context.

Authors:  Toshihiro Matsukawa; Mianmian Yin; Timour Baslan; Yang Jo Chung; Dengchao Cao; Ryan Bertoli; Yuelin J Zhu; Robert L Walker; Amy Freeland; Erik Knudsen; Scott W Lowe; Paul S Meltzer; Peter D Aplan
Journal:  FASEB J       Date:  2022-09       Impact factor: 5.834

4.  A NUP98-HOXD13 fusion gene impairs differentiation of B and T lymphocytes and leads to expansion of thymocytes with partial TCRB gene rearrangement.

Authors:  Chul Won Choi; Yang Jo Chung; Christopher Slape; Peter D Aplan
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

5.  Cre-loxP-mediated recombination between the SIL and SCL genes leads to a block in T-cell development at the CD4- CD8- to CD4+ CD8+ transition.

Authors:  Yue Cheng; Zhenhua Zhang; Christopher Slape; Peter D Aplan
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

6.  p16INK4A tumor suppressor gene expression and CD3epsilon deficiency but not pre-TCR deficiency inhibit TAL1-linked T-lineage leukemogenesis.

Authors:  Magali Fasseu; Peter D Aplan; Martine Chopin; Nicolas Boissel; Jean-Christophe Bories; Jean Soulier; Harald von Boehmer; François Sigaux; Armelle Regnault
Journal:  Blood       Date:  2007-05-16       Impact factor: 22.113

7.  Depletion of cytotoxic T-cells does not protect NUP98-HOXD13 mice from myelodysplastic syndrome but reveals a modest tumor immunosurveillance effect.

Authors:  Sheryl M Gough; Yang Jo Chung; Peter D Aplan
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

Review 8.  Role of the transcription factor Bcl11b in development and lymphomagenesis.

Authors:  Ryo Kominami
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

9.  Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.

Authors:  Diogo F T Veiga; Mathieu Tremblay; Bastien Gerby; Sabine Herblot; André Haman; Patrick Gendron; Sébastien Lemieux; Juan Carlos Zúñiga-Pflücker; Josée Hébert; Joseph Paul Cohen; Trang Hoang
Journal:  Front Immunol       Date:  2022-03-24       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.